Vitamin B12 — also known as cobalamin — is an essential micronutrient for nervous system function, DNA synthesis, and the production of red blood cells. Despite being present in animal-derived foods such as meat, eggs, and dairy, B12 deficiency is surprisingly common: it is estimated to affect between 6% and 39% of the adult population in different countries, with even higher rates among the elderly and vegetarians. What many people do not realize, however, is that genetics plays a determining role in this scenario — and that some individuals develop B12 deficiency even with an apparently adequate diet, simply because of variants in genes that control the absorption, transport, and metabolism of cobalamin.
Understanding how your DNA influences the way your body handles vitamin B12 is one of the most practical applications of modern nutrigenomics. This is not an abstract scientific curiosity: it is information that can guide supplementation choices, dietary decisions, and medical follow-up in a precise and personalized way.
Key finding: A study published in the American Journal of Clinical Nutrition estimated that up to 26% of the variation in serum vitamin B12 levels can be explained by genetic factors, independent of dietary intake. This means that two people eating the same amount of B12 can have dramatically different blood levels — and genetics is one of the central explanations.
The Journey of Vitamin B12 Through the Body: From Food to Metabolism
To understand how genes interfere with B12, it is first necessary to understand the complex path that cobalamin travels from food to the cell. Unlike other water-soluble vitamins, B12 absorption is a multi-step process, each step dependent on specific proteins — and therefore subject to the influence of genetic variants.
In the stomach, B12 from food is bound to proteins and must be released by the action of hydrochloric acid and pepsin. It then binds to haptocorrin (R protein), produced in the salivary glands, which protects it in the acidic gastric environment. In the duodenum, haptocorrin is degraded by pancreatic enzymes, releasing B12, which then binds to intrinsic factor (IF) — a glycoprotein secreted by the parietal cells of the stomach. The B12-IF complex travels to the terminal ileum, where it is recognized by a specific receptor called cubilin (encoded by the CUBN gene) and internalized by endocytosis. Inside intestinal cells, B12 is released and transferred to transcobalamin II (TC II), which transports it through the blood to the tissues. Finally, inside cells, B12 is converted into its active forms: methylcobalamin (cofactor for the MTR enzyme, used in the folate cycle) and adenosylcobalamin (cofactor for the MUT enzyme, used in propionate metabolism). Any disruption at any point along this pathway can result in functional B12 deficiency.
The Genes That Control Your B12: Mechanisms and Scientific Evidence
FUT2 — The Gatekeeper of Intestinal Absorption
The FUT2 gene (Fucosyltransferase 2, chromosome 19q13) encodes an enzyme responsible for expressing ABH blood group antigens on intestinal epithelial cells and body secretions (saliva, gastric juice). Individuals with two copies of loss-of-function variants in FUT2 are called non-secretors — and this status has surprising consequences for B12.
The most-studied SNP is rs601338 (G428A), which introduces a premature stop codon, eliminating enzymatic activity. Approximately 20% of Europeans are homozygous for this variant (non-secretors). GWAS published in Nature Genetics (Hazra et al., 2008) identified FUT2 as the locus with the greatest effect on serum B12 levels in the general population. Non-secretors have, on average, serum B12 levels approximately 18% higher than secretors — an apparent advantage. However, functional studies have revealed that this increase may reflect reduced absorption of inactive B12 analogues (which compete with true cobalamin), resulting in different proportions of active and inactive forms in the blood. Additionally, FUT2 status modifies the gut microbiota, indirectly affecting nutrient bioavailability.
TCN1 — The Transporter in the Stomach and Plasma
The TCN1 gene (Transcobalamin 1, chromosome 11q11) encodes haptocorrin (R protein), which, as described above, is the first B12-binding protein in the digestive tract. Variants in TCN1 alter the binding affinity or the amount of haptocorrin produced, modifying the efficiency of initial intestinal absorption.
The polymorphism rs526934 has been associated with significant variations in plasma haptocorrin levels and, consequently, in total blood B12. A study published in PLoS Genetics (Tanaka et al., 2009) identified TCN1 variants as independent contributors to serum B12 levels in a sample of more than 1,400 individuals. Carriers of certain TCN1 variants may have a reduced capacity to capture dietary B12 in the stomach, resulting in lower availability for absorption in the ileum — even with adequate intake.
TCN2 — The Systemic Transporter of B12
The TCN2 gene (Transcobalamin 2, chromosome 22q12) encodes transcobalamin II, the principal plasma carrier protein for B12. TC II is responsible for delivering absorbed cobalamin to virtually all cells in the body — including cells of the central nervous system and hematopoietic cells of the bone marrow.
The polymorphism c.776C>G (rs1801198), which results in a proline-to-arginine substitution at position 259 of the protein, is the most-studied variant. GG homozygotes show a 20 to 30% reduction in plasma holotranscobalamin concentration (the TC II fraction saturated with B12, considered the most sensitive indicator of functional B12 status). A study in the Journal of Nutrition (Namour et al., 2001) demonstrated that this variant affects TC II's affinity for its cellular receptors, reducing B12 uptake by tissues — creating functional deficiency even when total serum B12 levels appear normal.
MTRR — The Enzyme That Regenerates Active B12
The MTRR gene (5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase, chromosome 5p15) encodes methionine synthase reductase, the enzyme responsible for regenerating methylcobalamin to its active form after oxidation. Without adequate MTRR activity, the MTR enzyme (methionine synthase) becomes inactive — impairing the conversion of homocysteine to methionine and the synthesis of S-adenosylmethionine (SAM), the body's primary methyl group donor.
The A66G polymorphism (rs1801394) is the variant with the greatest clinical relevance. GG homozygotes show MTRR activity reduced by up to 50%, leading to accumulation of plasma homocysteine and impairment of the methylation cycle — even when serum B12 levels are considered "normal." Studies published in the American Journal of Human Genetics (Wilson et al., 1999) associated this variant with elevated risk of hyperhomocysteinemia, neural tube defects, and, when combined with MTHFR variants, significant impairment of one-carbon metabolism. This gene-gene interaction exemplifies the complexity of nutrigenomics: the impact of MTRR A66G is substantially amplified in the presence of MTHFR C677T variants.
MTR — The Central Enzyme of the Methylation Cycle
The MTR gene (5-Methyltetrahydrofolate-Homocysteine Methyltransferase, chromosome 1q43) encodes methionine synthase, the enzyme that uses methylcobalamin as a cofactor to convert homocysteine to methionine. It is the convergence point between B12 metabolism and folate metabolism.
The A2756G polymorphism (rs1805087) alters the structure of methionine synthase, reducing its stability and catalytic efficiency. G allele carriers tend toward mild hyperhomocysteinemia and may have greater demand for B12 to maintain normal enzyme function. Studies suggest that this variant interacts with B12 and folate status: in G allele carriers with inadequate B12 intake, homocysteine levels may be substantially higher than in AA individuals.
MMACHC — Intracellular Cobalamin Processing
The MMACHC gene (Methylmalonic Aciduria and Homocystinuria Type C, chromosome 1p34) encodes a chaperone protein responsible for intracellular cobalamin processing — the final step before B12 is converted into its active forms (methylcobalamin and adenosylcobalamin). Rare, large-effect mutations in MMACHC cause the severe metabolic disease cblC, one of the most common organic acidemias. Common variants of smaller effect, however, also contribute to subclinical variations in B12 metabolism in the general population, especially when associated with marginal nutrient intake.
Key Genes Involved in Vitamin B12 Metabolism
| Gene | Function | Impact on B12 |
|---|---|---|
| FUT2 | Controls expression of intestinal antigens that modulate absorption and microbiota | Non-secretors (GG) have an altered B12 profile; modifies absorption of inactive analogues |
| TCN1 | Encodes haptocorrin (R protein), the first B12-binding protein in the stomach | Variants reduce efficiency of initial dietary B12 capture |
| TCN2 | Encodes transcobalamin II, systemic B12 transporter to all tissues | 776C>G variant reduces holotranscobalamin by 20–30%; functional deficiency with normal total B12 |
| MTRR | Regenerates active methylcobalamin after oxidation; essential for keeping MTR active | A66G reduces activity by up to 50%; elevates homocysteine; amplified by MTHFR variants |
| MTR | Converts homocysteine to methionine using methylcobalamin as cofactor | A2756G reduces enzyme stability; increases B12 demand to normalize homocysteine |
| MMACHC | Processes intracellular cobalamin for synthesis of methylcobalamin and adenosylcobalamin | Rare variants cause severe disease; common variants contribute to suboptimal metabolism |
Clinical Manifestations: When Genetics Compromises B12
Functional vitamin B12 deficiency — whether from inadequate intake, poor absorption, or genetic metabolic impairment — manifests in various ways, often insidiously. The best-documented consequences include:
- Megaloblastic anemia: deficient production of functional red blood cells, with large, immature cells, causing fatigue, pallor, and shortness of breath.
- Peripheral neuropathy: demyelination of peripheral nerves, with paresthesias (tingling), muscle weakness, and balance disturbances — often irreversible if not treated early.
- Hyperhomocysteinemia: elevated plasma homocysteine, an independent risk factor for cardiovascular disease, stroke, and deep vein thrombosis.
- Cognitive impairment: memory deficits, concentration difficulties, and, in severe cases, dementia syndrome — especially in the elderly.
- Mood disturbances: depression, irritability, and anxiety associated with impairment of neurotransmitter synthesis dependent on the methylation cycle.
"Genetic variants affecting vitamin B12 metabolism can cause functional deficiency even in the presence of apparently adequate dietary intake — and serum B12 levels alone are insufficient to detect this." — American Journal of Clinical Nutrition, 2013
Practical Implications: What to Do With This Information
Knowing your genetic profile related to B12 transforms abstract information into concrete action. Here are the most relevant practical implications:
Food Sources and Bioavailability
The best sources of vitamin B12 are animal-derived foods: beef liver (78 µg/100g), clams (98 µg/100g), red meats (2–3 µg/100g), fish (especially salmon and tuna), eggs, and dairy products. For individuals with variants that compromise intestinal absorption (FUT2, TCN1), maximizing source diversity and prioritizing high-bioavailability foods is especially important. Vegetarians and vegans with risk variants have a particularly elevated need for supplementation.
Supplementation Forms
For individuals with variants in MTRR or MTR — which compromise the conversion of B12 into its active form — supplementation with methylcobalamin (the already-active form) may be more effective than cyanocobalamin (the most common and inexpensive form of supplements). Methylcobalamin enters the methylation cycle directly without requiring enzymatic conversion, bypassing the bottleneck created by genetic variants. In cases of severe intestinal absorption impairment (such as in carriers of TCN2 variants), sublingual or intramuscular supplementation may be necessary.
Laboratory Monitoring
Individuals with TCN2 variants deserve special attention: as this polymorphism can cause functional deficiency with apparently normal total serum B12, it is recommended to measure holotranscobalamin (active B12) and plasma homocysteine in addition to total B12 — far more sensitive indicators of functional status. Urinary or serum methylmalonic acid (MMA) is another useful marker of functional deficiency.
Gene-Gene and Gene-Nutrient Interactions
Carriers of variants in both MTRR and MTHFR (especially the C677T polymorphism) should be made aware of the importance of simultaneously maintaining adequate levels of both B12 and folate — since the two metabolic cycles are interdependent. Deficiency in one amplifies the impact of deficiency in the other, generating more severe metabolic impairment than would be expected from each variant individually.
What helixXY Can Reveal
The helixXY genetic report analyzes variants in the key genes involved in vitamin B12 metabolism — including FUT2, TCN1, TCN2, MTRR, and MTR — and translates these findings into personalized, actionable nutritional recommendations.
Based on your individual genetic profile, helixXY can reveal:
- Whether you are a secretor or non-secretor (FUT2) and what this means for your intestinal absorption of B12;
- Whether you have TCN2 variants that require monitoring of holotranscobalamin rather than total B12;
- Whether MTRR variants compromise your ability to regenerate active methylcobalamin — and whether methylcobalamin supplementation would be more appropriate for you than cyanocobalamin;
- Whether the interaction between your B12 genes and MTHFR creates a need for heightened attention to the methylation cycle;
- Which laboratory markers are most informative for monitoring your actual B12 status, given your specific genetic profile.
This approach represents precision nutrition in its most applied form: not the generic recommendation to "take B12," but personalized guidance on which form, at what dose, by which route, and with which follow-up tests — all based on your DNA.
Important: helixXY reports are informational and educational. Consult a healthcare professional before starting or changing any supplementation protocol, especially if you have neurological, hematological, or cardiovascular symptoms that may be related to vitamin B12 deficiency.
References
- Hazra A, Kraft P, Selhub J, et al. Common variants of FUT2 are associated with plasma vitamin B12 levels. Nature Genetics. 2008;40(10):1160-2.
- Tanaka T, Scheet P, Giusti B, et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. American Journal of Human Genetics. 2009;84(4):477-82.
- Namour F, Olivier J, Abdelmouttaleb I, et al. Transcobalamin codon 259 polymorphism in HT-29 and Caco-2 cells and in Caucasians: relation to transcobalamin and homocysteine concentration in blood. Blood. 2001;97(4):1092-8.
- Wilson A, Platt R, Wu Q, et al. A common variant in methionine synthase reductase combined with low cobalamin increases risk for spina bifida. Molecular Genetics and Metabolism. 1999;67(4):317-23.
- Carmel R, Garrow TA. The biochemistry and physiology of homocysteine and its relation to vitamin B12 status. American Journal of Clinical Nutrition. 2013;97(3):543-50.
